Brought to you by 
Oscient gets US rights to Reliant's Antara
23 Aug 2006
Executive Summary
Reliant Pharmaceuticals (branded cardiovascular drugs) licensed infectious disease company Oscient Pharmaceuticals exclusive US rights to the adjunct therapy Antara (fenofibrate) 43mg and 130mg capsules for hypercholesterolemia and hypertriglyceridemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oscient gets US rights to Reliant's Antara
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice